CYP2C9 and CYP3A4 (CYP2C9 and CYP3A4)

Molecular Classification

Enzyme, Oxidoreductase, Cytochrome P450 superfamily

Other Names

Cytochrome P450 2C9, Cytochrome P450 3A4, P450 enzymes, CYP2C9 enzyme, P450 2C9, CYP3A4 enzyme, P450 3A4

Disease Roles

Pharmacogenetic variability impacting therapeutic responseAdverse drug reactions due to loss/gain-of-function allelesDrug-drug interactions

CYP2C9 and CYP3A4 Overview

CYP2C9 and CYP3A4 are highly expressed enzymes of the cytochrome P450 family found predominantly in the liver. Each enzyme catalyzes the oxidation of xenobiotics and endogenous compounds, playing an essential role in phase I drug metabolism. CYP2C9 metabolizes about 15% of all prescription drugs, including several with a narrow therapeutic index. CYP3A4, the most abundant CYP in human liver, participates in the metabolism of over 50% of clinically used drugs. Both enzymes exhibit genetic polymorphisms that significantly impact individual drug responses, efficacy, and risk of adverse reactions. Clinical genotyping and drug monitoring are essential for drugs highly dependent on these enzymes for clearance. Both are major targets in drug development and in clinical risk management for drug interactions and precision medicine.

Mechanism of Action

Drugs targeting these enzymes may act as inhibitors (reduce enzyme activity; e.g., amiodarone, metronidazole, miconazole for CYP2C9; ketoconazole, grapefruit juice for CYP3A4). Inducers (increase enzyme activity; e.g., rifampin, barbiturates, carbamazepine for both). Substrates (drugs metabolized by these enzymes). Genetic variants alter enzyme function, changing drug metabolism rate.

Biological Functions

Drug metabolism (oxidation of xenobiotics, including many clinical drugs)

Metabolism of endogenous substrates (e.g., fatty acids, hormones)

Detoxification

Disease Associations

Pharmacogenetic variability impacting therapeutic response

Adverse drug reactions due to loss/gain-of-function alleles

Drug-drug interactions

Treatment failure and toxicity due to altered metabolism rates (not a disease, but a clinically relevant risk)

Safety Considerations

Drug-drug interactions: Enzyme inhibition or induction alters drug clearance, risking toxicity or treatment failure
Pharmacogenetic variability: Poor or ultra-rapid metabolizers may have adverse drug reactions or subtherapeutic effects
Narrow therapeutic index drugs are especially at risk (warfarin, phenytoin, etc.)
Polymorphisms in genes lead to significant interindividual variability, requiring patient-specific dose adjustments
Grapefruit juice and other foods/herbals may alter CYP3A4 activity, causing unexpected effects

Interacting Drugs

Warfarin

phenytoin

tolbutamide

nonsteroidal anti-inflammatory drugs (NSAIDs: ibuprofen, naproxen, flurbiprofen, diclofenac)

oral hypoglycemics (glipizide)

angiotensin II receptor blockers (losartan)

Tamoxifen

zolpidem

erythromycin

prednisolone

carbamazepine

fentanyl

nifedipine

loratadine

simvastatin

cyclosporine

Associated Biomarkers

Biomarker
CYP2C9 and CYP3A4 genotyping (diplotype/activity score for CYP2C9, specific alleles for CYP3A4)
Drug plasma levels (warfarin, phenytoin, tacrolimus, simvastatin, etc.) to monitor efficacy/toxicity relating to metabolic activity